Curanex Pharmaceuticals Inc CURX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to

treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients'

lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines

for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with

Last close 4.64 2026-10-23
Market cap $145.5M 2026-06-30 share count
52-week range 3.58 - 16.60

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.17

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
R&D $3.0M——
SG&A $1.3M$290.4K—
Total operating expenses $4.2M$365.1K—
Operating income -$4.2M-$365.1K—
Interest expense $8.5K——
Net income -$4.2M-$361.5K—
EPS, basic -0.17-0.03—
EPS, diluted -0.17-0.03—
Shares, diluted (wtd. avg.) 25.5M13.3M—

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $5.0M——
Total current assets $11.2M$517.9K—
Total assets $11.6M$517.9K—
Accounts payable $2.4K$5.0K—
Total current liabilities $137.0K$14.6K—
Total liabilities $361.0K$14.6K—
Retained earnings -$4.8M-$622.4K—
Total equity $11.2M$503.4K$60.1K

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$10.5M-$555.6K—
Financing cash flow $15.3M$630.1K—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013677.

Plot the figures US dollars

  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -6M -4M -2M 0 Net income, FY2024: -361.5K Net income, FY2025: -4.2M FY2023 FY2024 FY2025
Fiscal year FY2023FY2024FY2025
Revenue — — —
Gross profit — — —
Net income — -$361.5K -$4.2M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%